TNFRSF13C and atherosclerosis: In mice, disruption of BAFFR signaling results in ablation of, among others, conventional mature B-2 cells (follicular and marginal zone B cells), a very similar phenotype to anti-CD20 antibody (Ab)–treated mice.5–9 BAFFR-deficient, anti-BAFFR Ab–treated, and anti-CD20–treated mice display reduced atherosclerosis,5–9 suggesting that B-2 cells exhibit proatherogenic properties, and that targeting the BAFFR signaling pathway may be a therapeutic option for combating atherosclerotic CVD.